IFNG and neoplasm: Yukiko et al. discovered that the combination of PD-L1 inhibitors with CAR-T cell therapy transformed the phenotype of TAMs into an M1-like subset that has no inhibitory effect on CAR-T cells through IFN-γ signaling and led to a depletion of CD163 + M2 macrophages, thus bolstering the anti-tumor efficacy of CAR-T cells [73].